Financial Reports
Related Searches:
Filter by:
July 22, 2009
New business awards in the quarter were $266 million, representing a book-to-bill ratio of 1.2.
Read More »
July 21, 2009
Worldwide sales of Singulair were $1.3 billion in the quarter (+ 16%). Combined sales of Zetia and Vytorin, as reported by the Merck/Schering-Plough partnership, were $1.0 billion (-10%).
Read More »
July 21, 2009
Pharmaceutical sales were down 3% in the quarter to $3.6 billion, reflecting 7% operational growth and an unfavorable impact from foreign exchange of 10%.
Read More »
July 16, 2009
Sales in the quarter and YTD were up 8% in local currencies (lc), but were impaired by fluctuations in exchange rates.
Read More »
July 16, 2009
Growth in the quarter was driven by Tysabri sales, up 27% to $188 million, and Avonex sales, up 12% to $591 million.
Read More »
July 15, 2009
Worldwide pharmaceutical sales were $3.9 billion (-4%).
Read More »
July 14, 2009
Worldwide pharmaceutical sales were $5.5 billion in the quarter (-13%), including a 5% negative impact from currency.
Read More »
June 12, 2009
Exchange rate fluctuation affected most results for the quarter. Commercial manufacturing revenues were down 11% to $135.2 million, but gross profit rose by $2.0 million from 2Q08.
Read More »
May 15, 2009
Growth in the quarter was driven primarily by 28% growth in revenues for China-based Lab Services to $41.6 million, offset by an 81% decline in manufacturing services revenue.
Read More »
May 7, 2009
Oncaspar sales were up 15% to $14.1 million. DepoCyt sales were $2.5 million (+25%).
Read More »
May 6, 2009
Preclinical Services revenue was $140.0 million (-17%) due primarily to slower market demand.
Read More »
May 1, 2009
Product sales were $994.6 million in the quarter.
Read More »
April 30, 2009
U.S. sales were $3.6 billion (+7%), aided by Toprol-XL sales, up 59% to $288 million, due to the withdrawal of two generic competitors.
Read More »
April 30, 2009
Early development revenues were $192.5 million (-5%). Late-stage development revenues were up 18% to $248.7 million.
Read More »
April 29, 2009
Pharmaceutical sales were $8.6 billion (-1%). Lovenox sales were $1.0 billion (+1%).
Read More »
